Get the Stockscreener App
25.45
3.48%
0.65
Crescent Biopharma Inc stock is traded at $25.45, with a volume of 17,384.
It is up +3.48% in the last 24 hours and up +69.29% over the past month.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
See More
Previous Close:
$24.80
Open:
$24.54
24h Volume:
17,384
Relative Volume:
0.08
Market Cap:
$778.00M
Revenue:
$10.84M
Net Income/Loss:
$-141.14M
P/E Ratio:
-1.658
EPS:
-15.3501
Net Cash Flow:
$-144.45M
1W Performance:
+18.32%
1M Performance:
+69.29%
6M Performance:
+97.42%
1Y Performance:
+4,919%
1-Day Range:
$24.54
$25.87
1-Week Range:
$20.40
$27.41
52-Week Range:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Name
Crescent Biopharma Inc
Sector
Industry
Phone
617-430-5595
Address
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
25.54 | 755.46M | 10.84M | -141.14M | -144.45M | -15.35 |
VRTX
Vertex Pharmaceuticals Inc
|
431.34 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.82 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
790.88 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
311.27 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
301.28 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Jan-21-26 | Initiated | Guggenheim | Buy |
| Aug-25-25 | Initiated | Jefferies | Buy |
| Aug-11-25 | Initiated | H.C. Wainwright | Buy |
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
Crescent Biopharma Grants Equity Inducement Awards to New Employees as Part of 2025 Incentive Plan - Quiver Quantitative
New Crescent hires receive stock options priced at Nasdaq's $25.70 close - Stock Titan
CBIO Price Today: Crescent Biopharma, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Stifel Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
Crescent Bio (CBIO) Stock: Is It Losing Momentum | Q4 2025: Better Than ExpectedWall Street Picks - Xã Châu Thành
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Crescent Biopharma (CBIO) - The Globe and Mail
CRESCENT BIOPHARMA, INC. ($CBIO) CEO & Director 2025 Pay Revealed - Quiver Quantitative
Form DEFA14A CRESCENT BIOPHARMA, INC. - StreetInsider
Crescent Biopharma (NASDAQ: CBIO) outlines 2026 AGM votes on board, pay and auditor - Stock Titan
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Piper Sandler Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) vs. Crescent Biopharma (NASDAQ:CBIO) Head to Head Review - Defense World
Crescent Biopharma Stock On Fire: Up 86% With 7-Day Winning Streak - Trefis
Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree - Trefis
Crescent Biopharma Stock Surges 85%, With A 6-Day Winning Spree - Trefis
Crescent Biopharma Stock Rockets 85% With 6-Day Winning Streak - Trefis
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above 200-Day Moving AverageTime to Sell? - MarketBeat
CBIO Shows Strength: Technical Breakout Imminent - Cổng thông tin điện tử Tỉnh Sơn La
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
Three new Crescent Biopharma hires get stock options at $13.50 - Stock Titan
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Crescent Biopharma, Inc. (CBIO) Fundamental Analysis - meyka.com
Why Is Crescent Biopharma, Inc. (CBIO) Stock Down Today? - Meyka
Crescent Biopharma, Inc.: Fundamental Analysis and Financial Ratings | | US38000Q2012 - marketscreener.com
CBIO PE Ratio & Valuation, Is CBIO Overvalued - Intellectia AI
Crescent Biopharma (NASDAQ: CBIO) registers 19.58M resale shares from private placement - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Upgraded to Hold at Wall Street Zen - MarketBeat
HC Wainwright Has Optimistic Outlook of CBIO Q1 Earnings - Defense World
Two Crescent Biopharma employees granted 45,675 stock options - Stock Titan
HC Wainwright Issues Optimistic Estimate for CBIO Earnings - MarketBeat
GLYC SEC FilingsGlycomimetics 10-K, 10-Q, 8-K Forms - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Given New $22.00 Price Target at HC Wainwright - Defense World
Crescent Biopharma (NASDAQ: CBIO) registers 19.58M resale shares after $185M placement - Stock Titan
CBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright - MarketBeat
H.C. Wainwright cuts Crescent Biopharma stock price target to $22 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Crescent Biopharma stock price target to $22 - Investing.com Australia
Crescent BiopharmaFinancial Details - Crunchbase
A Look At Sichuan Kelun-Biotech Biopharmaceutical’s Valuation After The Crescent Biopharma Oncology Partnership - simplywall.st
Guggenheim Remains a Buy on Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma (CBIO) Posts US$10.8m Q4 Revenue Against Heavy Losses Challenging Bullish Narratives - simplywall.st
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Crescent Biopharma (CBIO) - The Globe and Mail
Stifel cuts Crescent Biopharma stock price target on equity financing - Investing.com South Africa
Stifel cuts Crescent Biopharma stock price target on equity financing By Investing.com - Investing.com Canada
Crescent Biopharma: Q4 Earnings Snapshot - theheraldreview.com
Crescent Biopharma Inc recently disclosed that certain revenues recognized in its 2025 financial report actually originate from a $20 million upfront payment made by Kelun-Biotech under a licensing agreement between the two parties for the core asset Cr-00 - Bitget
CBIO: Expanded oncology pipeline and strong cash position support multiple clinical milestones into 2028 - TradingView
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent ... - Bluefield Daily Telegraph
Crescent Biopharma (Nasdaq: CBIO) ramps R&D with $185M raise and 2025 loss - Stock Titan
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):